Loading...
Docoh

Bioxytran (BIXT)

Filed: 12 Mar 20, 7:59am

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 12, 2020

 

BIOXYTRAN, INC.

(Exact Name if Business Issuer as specified in its Charter)

 

Nevada 001-35027 26-2797630
(State or other Jurisdiction
of Incorporation)
 (Commission
File Number)
 (IRS Employer
Identification Number)

 

233 Needham Street,

Suite 300

Newton MA, 02464

(Address of principal executive offices, including zip code)

 

(617) 494-1199
(Registrant’s telephone number including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)
  
Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))
  
Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common BIXT OTCQB

 

 

 

 

 

 

Item 8.01. Other Events.

 

Dr. David Platt has been invited to be a guest presenter on the perfusionist network which is a continuing education forum for perfusionists on March 26, 2020 in MediWeb Studios, Magnolia, TX. The program is broadcast live on the PerfWeb, and all major social media platforms like Twitter, Facebook, LinkedIn and immediately available for rebroadcast from their YouTube channel.

 

On March 12, 2020, Bioxytran released a presentation with a new potential application for its compounds which will be used at this event. The presentation is attached hereto as Exhibit 99.1 hereto.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit  
Number Description
   
99.1 BioxyTran, Inc. Presentation, dated March 12, 2020.

  

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 By:/s/ Dr. David Platt
 Name: Dr. David Platt
 Title:President and Chief Executive Officer
  
 Dated:  March 12, 2020

 

 

2